Selecta Biosciences to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Selecta Biosciences, Inc. (NASDAQ: SELB) announced participation in two investor conferences in August 2022. The BTIG Biotechnology Conference will take place virtually from August 8-9, focusing on one-on-one meetings. The Canaccord Genuity 42nd Annual Growth Conference is scheduled for August 10 in Boston, featuring a fireside chat at 2:30 p.m. ET. Selecta utilizes its ImmTOR® platform to develop therapies for autoimmune diseases and enhance gene therapies. More details can be found on their website.

WATERTOWN, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR^® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, today announced that Company’s Management will participate in upcoming investor conferences in August.

Details on the conferences can be found below.

BTIG Biotechnology Conference 2022
Format: One-on-one investor meetings, attending virtually
Date: Monday, August 8 to Tuesday, August 9, 2022
Location: New York, NY

BTIG hosted events are intended for prospective and existing BTIG clients only. To schedule a meeting with the Company, please contact your BTIG representative.

Canaccord Genuity 42nd Annual Growth Conference
Format: Fireside chat and one-on-one investor meetings, attending in-person
Date: Wednesday, August 10, 2022
Time: 2:30 p.m. ET
Location: Boston, MA
Webcast: Click Here

An archived webcast of the Canaccord presentation will be accessible in the Investors & Media section of the company’s website at www.selectabio.com.

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.

For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com

For Media: 
Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-646-751-4366
bleigh@lifescicomms.com

FAQ

What are the details of Selecta Biosciences' participation in the BTIG Biotechnology Conference?

Selecta Biosciences will participate in the BTIG Biotechnology Conference virtually from August 8 to 9, 2022, with one-on-one investor meetings scheduled.

When will Selecta Biosciences participate in the Canaccord Genuity Annual Growth Conference?

Selecta Biosciences will attend the Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022, starting at 2:30 p.m. ET in Boston.

What is the significance of Selecta Biosciences' ImmTOR platform?

Selecta Biosciences' ImmTOR platform is designed to develop tolerogenic therapies to mitigate unwanted immune responses and enhance the efficacy of biologic therapies.

Where can I find the webcast for the Canaccord Genuity conference presentation?

An archived webcast of the Canaccord presentation will be accessible in the Investors & Media section of Selecta Biosciences' website.

What focus areas does Selecta Biosciences concentrate on?

Selecta Biosciences focuses on developing therapies for autoimmune diseases, enhancing gene therapies, and mitigating immune responses using its ImmTOR platform.